The Labs Your Doctor Didn't Run (Pre-Protocol Bloodwork Blueprint)

Your doctor checks total testosterone, sees a number inside the reference range, and tells you everything looks fine. And in a narrow technical sense, they are not wrong. But a single number without context cannot tell you whether that testosterone is actually reaching your cells, whether your brain is even sending the signal to make it, or whether the system around it is quietly breaking down in ways that will show up years later as a real problem.

This is what a complete pre-protocol panel actually looks like, and more importantly, why each piece of it matters.

Start with the full hormonal picture, because testosterone does not operate alone. The Endocrine Society guideline from 2018 specifies that diagnosis requires two fasting morning total testosterone measurements, not one, and that you have to distinguish between primary and secondary hypogonadism using LH and FSH before you can even think about treatment. That distinction matters more than most people realize.

LH and FSH are the signals your brain sends to your testes telling them to produce testosterone. If total testosterone is low and LH is also low, the problem is upstream, meaning your brain is not sending the signal, and that is called secondary hypogonadism. If total testosterone is low but LH is high, your brain is screaming at your testes and they are not responding, and that is primary hypogonadism. These two scenarios look identical on a single testosterone test, but they have completely different causes and completely different treatment implications.

Now add SHBG to that picture, which stands for sex hormone binding globulin, and it is a protein in your blood that binds to testosterone and holds it in a form your cells cannot use. Think of it as a locked transport vehicle. The testosterone is technically there, but it cannot get out. This is why a man with 600 ng/dL total testosterone and high SHBG can have less biologically active testosterone than a man sitting at 400 ng/dL with low SHBG. The harmonized reference range from a study of 9,054 men puts normal total testosterone between 264 and 916 ng/dL, which is an enormous window, and SHBG is a large part of what determines where someone falls on that range functionally.

Estradiol, prolactin, DHEA-sulfate, progesterone, and cortisol complete the hormonal layer. Elevated prolactin can suppress the entire axis and is sometimes the actual cause of low testosterone, and cortisol gives you a window into chronic stress load, which directly suppresses LH and reproductive hormone output. Skipping these is like troubleshooting a car engine while leaving half the hood closed.

One more note on estradiol specifically: measuring it accurately in men requires a testing method called LC-MS/MS, which stands for liquid chromatography tandem mass spectrometry, and it is the only method sensitive enough to accurately detect the lower estradiol levels typical in men. Standard immunoassay tests, which is what most labs run by default, are calibrated for female ranges and will frequently give you inaccurate readings in men. You have to ask for the sensitive assay.

The second layer is metabolic health. A comprehensive metabolic panel, hemoglobin A1c, and fasting insulin. Most standard panels will include fasting glucose but stop there, and that gap matters because glucose and insulin tell you fundamentally different things. Glucose tells you where blood sugar is right now. Insulin tells you how hard your pancreas is working to keep it there.

You can have completely normal fasting glucose while insulin is already running two to three times higher than it should be, because the pancreas is compensating by flooding your system with insulin to manage a load it should not have to manage. That state is called insulin resistance, and it is already damaging your metabolic system before glucose ever becomes abnormal. Catching it only at the glucose stage is like checking whether your house is on fire by waiting to see smoke coming out the windows.

The third layer is cardiovascular risk. A full lipid panel is the starting point, but the two markers that actually predict events are apolipoprotein B and high sensitivity C-reactive protein. Standard cholesterol numbers tell you how much cholesterol is in your blood. ApoB tells you how many lipoprotein particles are carrying it, because it is the particle count, not the cholesterol content, that drives plaque buildup in arterial walls. Two people with the same LDL cholesterol number can have radically different ApoB counts and radically different cardiovascular risk profiles.

High sensitivity C-reactive protein, or hs-CRP, measures active systemic inflammation, which is a separate and independent risk factor for cardiovascular events that standard lipid panels do not capture at all.

The fourth layer is baseline safety markers. A complete blood count with differential gives you hematocrit, which measures the proportion of your blood that is red blood cells. This matters before starting testosterone because testosterone stimulates red blood cell production, and if hematocrit climbs too high, blood viscosity increases in a way that raises clotting risk. A 2022 study in the Journal of Urology found that men on testosterone therapy with hematocrit at or above 52 percent had a 35 percent higher risk of major adverse cardiovascular events and venous thromboembolism compared to those with normal levels. You need to know where hematocrit is before you start, so you have a real baseline to track against.

TSH, free T3, and free T4 give you thyroid function, because hypothyroidism and hypogonadism share enough symptoms that one is regularly mistaken for the other, and treating testosterone when the thyroid is the actual problem will not fix anything. PSA is a baseline prostate marker. And IGF-1, which is insulin-like growth factor 1, is a downstream marker of growth hormone activity, and it needs to be measured before starting any growth hormone peptide protocol so you actually have something to compare to when you want to know whether the protocol is working.

Most people think of bloodwork as a checklist you do once to confirm you are allowed to start treatment. But what this panel actually is, is a map of the system you are about to intervene on, and you cannot design a rational intervention without knowing the starting state of every part of that system.

A single testosterone number tells you almost nothing about what is driving it, what is binding it, what is inflaming around it, or what will happen when you change it. The whole panel tells you the whole story.

---

References

1. Bhasin S et al. Testosterone Therapy in Men With Hypogonadism. JCEM. 2018 — Endocrine Society guideline: diagnosis requires two fasting morning total T measurements, distinguish primary vs secondary via LH/FSH
2. Mulhall JP et al. Evaluation and Management of Testosterone Deficiency. AUA Guideline. J Urology. 2018 — Total T below 300 ng/dL threshold, recommend LH in all men with low T
3. Travison TG et al. Harmonized Reference Ranges for Circulating Testosterone Levels. JCEM. 2017 — 9,054 men, harmonized range 264-916 ng/dL
4. Ory J et al. Secondary Polycythemia in Men Receiving Testosterone Therapy. J Urology. 2022 — Hematocrit >=52% on TRT = 35% higher MACE/VTE risk (OR 1.35)
5. Rosner W et al. Toward Excellence in Testosterone Testing. JCEM. 2013 — Sensitive LC-MS/MS required for accurate male estradiol

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness